Preclinical activity of melflufen (J1) in ovarian cancer.

about

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3',4',5'-trimethoxychalcone in rodents.

P2860

Q42371678-1D5B64F2-B10C-4BCE-9710-D793F05EA51A Q50146011-144EBA57-F178-43C5-8258-131C37881F60

P2860

Preclinical activity of melflufen (J1) in ovarian cancer.

Item

http://www.wikidata.org/entity/Q37644866

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical activity of melflufen (J1) in ovarian cancer.

@en

Preclinical activity of melflufen

@nl

type

Item

label

Preclinical activity of melflufen (J1) in ovarian cancer.

@en

Preclinical activity of melflufen

@nl

prefLabel

Preclinical activity of melflufen (J1) in ovarian cancer.

@en

Preclinical activity of melflufen

@nl

P1476

Preclinical activity of melflufen (J1) in ovarian cancer.

@en

P2093

Charlotte Carlier

http://www.w3.org/2001/XMLSchema#string

Ebba Velander

http://www.w3.org/2001/XMLSchema#string

Elly De Vlieghere

http://www.w3.org/2001/XMLSchema#string

Jack Spira

http://www.w3.org/2001/XMLSchema#string

Joachim Gullbo

http://www.w3.org/2001/XMLSchema#string

Kristina Viktorsson

http://www.w3.org/2001/XMLSchema#string

Maria Uustalu

http://www.w3.org/2001/XMLSchema#string

Rolf Lewensohn

http://www.w3.org/2001/XMLSchema#string

Sara Strese

http://www.w3.org/2001/XMLSchema#string

Therese Juntti

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells.

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

Therapeutic strategies for targeting the ovarian tumor stroma.

Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Guidelines for the welfare and use of animals in cancer research.

Matrigel: a complex protein mixture required for optimal growth of cell culture.

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.

P304

59322-59335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.11163

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Nygren

Rolf Larsson

P577

2016-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27528037

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5312315

http://www.w3.org/2001/XMLSchema#string

Preclinical activity of melflufen (J1) in ovarian cancer.

about

P2860

P2860

Preclinical activity of melflufen (J1) in ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932